Answers are grounded in this paper and cite their sources.
Treatments for patient with ankylosing spondylitis (AS) include non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs) and anti-tumor necrosis factor-alpha (TNFα) agents.However, owing to the well-known nephrotoxicity of NSAIDs and some DMARDs, the use of these drugs is limited in AS patients with renal insufficiency.As the pharmacokinetics and metabolism of anti-TNFα agents in patients of end stage renal disease, especially those receiving peritoneal di-alysis (PD), have not been investigated well, little is known about treating them with anti-TNFα agents.We described the safety and efficacy of etanercept, a soluble fusion protein comprising the TNF receptor 2 in linkage with the Fc portion of immunoglobulin G, in a 40-year-old male AS patient receiving PD.
No takes yet. Share an insight, caveat, or question.
Choi et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: